filmov
tv
Lu-PSMA Radioligand Therapy
Показать описание
As part of the 2022 Prostate Cancer Patient Conference, Dr. Thomas Hopes discusses advanced prostate cancer and PSMA-lutetium. Recorded on 10/15/2022. [Show ID: 38578]
Please Note: Knowledge about health and medicine is constantly evolving. This information may become out of date.
More from: Prostate Cancer Patient Conference
Explore More Health & Medicine on UCTV
UCTV features the latest in health and medicine from University of California medical schools. Find the information you need on cancer, transplantation, obesity, disease and much more.
UCTV is the broadcast and online media platform of the University of California, featuring programming from its ten campuses, three national labs and affiliated research institutions. UCTV explores a broad spectrum of subjects for a general audience, including science, health and medicine, public affairs, humanities, arts and music, business, education, and agriculture. Launched in January 2000, UCTV embraces the core missions of the University of California -- teaching, research, and public service – by providing quality, in-depth television far beyond the campus borders to inquisitive viewers around the world.
Please Note: Knowledge about health and medicine is constantly evolving. This information may become out of date.
More from: Prostate Cancer Patient Conference
Explore More Health & Medicine on UCTV
UCTV features the latest in health and medicine from University of California medical schools. Find the information you need on cancer, transplantation, obesity, disease and much more.
UCTV is the broadcast and online media platform of the University of California, featuring programming from its ten campuses, three national labs and affiliated research institutions. UCTV explores a broad spectrum of subjects for a general audience, including science, health and medicine, public affairs, humanities, arts and music, business, education, and agriculture. Launched in January 2000, UCTV embraces the core missions of the University of California -- teaching, research, and public service – by providing quality, in-depth television far beyond the campus borders to inquisitive viewers around the world.
Lu-PSMA Radioligand Therapy
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC
Treatment for Advanced Prostate Cancer Patients | Lutetium 177 PSMA Radioligand Therapy | Mercy
How I Select Patients for Lutetium-PSMA Radioligand Therapy
Chemotherapy and Radioligand Therapy for Advanced Prostate Cancer
CAT 3: PSMA Radioligand Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by PSMA PET/CT
PSMA Targeting for Treatment of Advanced Prostate Cancer - 2021 Prostate Cancer Patient Conference
EANM2020 - Dosimetry and Radiobiology of Lu PSMA treatment whole body tumour dose by Dr John Violet
Lu 177 PSMA therapy for Prostate cancers #ProstateCancer #LutetiumPSMAtherapy #PSMAPET #narveshkumar
How to administer the investigational radiopharmaceutical 177Lu-PSMA-I&T
ECLIPSE - A Randomized Phase 3 Trial for 177-Lu-PSMA-I&T in patients with mCRPC
Fernando Acosta's Testimonial with Lutetium-177 PSMA Radioligand Therapy.
Integrating radioligand therapy for prostate cancer in US clinical practice
Remaining questions regarding PSMA radioligand therapies
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
PSMA-Targeted PET Imaging & Radioligand Therapy in the Management of Prostate Cancer
ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC
Radioligand therapy for mCRPC
PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer
PCa Commentary May 2021 - PSMA Targeted RadioIigand Therapy for Metastatic Prostate Cancer
Safety and Efficacy of 177Lu-PSMA-617
177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)
VISION: Lu-177-PSMA-617 in mCRPC
Living with Prostate Cancer: Lutetium 177 Therapy Treatment | Mercy Radiology
Комментарии